Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05006079 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

Study acronym: MAP
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 2025 to Dec 2026
    • Study completion date: Dec 2025 to Dec 2026
    v9
  2. Re-verified, no change to tracked fieldsv8
  3. Start date: Jun 15, 2022 to Mar 13, 2024v7
  4. Study completion date: Oct 2025 to Dec 2025
    • Eligibility criteria expanded, about 27 words
    v6
  5. Primary completion date: Aug 2024 to Aug 2025
    • Study completion date: Dec 2024 to Oct 2025
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2022 to Jun 15, 2022
    v4
  2. Start date: Feb 2022 to May 2022v3
  3. Start date: Oct 2021 to Feb 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.
Trial Details
NCT Number NCT05006079
Lead Sponsor Wayne State University
Collaborators: Henry Ford Health System
Conditions
(from sponsor)		 Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse
Related terms Opioid-Related Disorders
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov